<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099319</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-1001-CU</org_study_id>
    <nct_id>NCT01099319</nct_id>
  </id_info>
  <brief_title>Renalof in the Treatment of Elderly Patients With Gallstones</brief_title>
  <official_title>Efficacy and Safety of Renalof Administration in the Treatment of Elderly Patients With Gallstones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Renalof administration in
      the treatment of gallstones (cholelithiasis) as determined by ultrasonography and clinical
      evaluation in elderly patients (aged &gt;65 years). The duration of this double-blind placebo
      controlled phase 3 clinical trial will be 6 months. The estimated number of patients to be
      recruited and randomized for the study is 40.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of calculi at month 0 and 6 (month 0 refers to the beginning of treatment and month 6 refers to the end of the treatment)</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of calculi at month 0 and 6 (month 0 refers to the beginning of treatment and month 6 refers to the end of the treatment)</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of digestive symptoms associated with cholelithiasis</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects during treatment</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cholelithiasis</condition>
  <arm_group>
    <arm_group_label>Renalof</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Renalof</intervention_name>
    <description>One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.</description>
    <arm_group_label>Renalof</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One Placebo tablet (Orally administered) every 8 hours, for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmation of cholelithiasis by ultrasonography with or without clinical symptoms.

          -  Signed informed consent

        Exclusion Criteria:

          -  Previous surgical intervention for the treatment of cholelithiasis

          -  Cholelithiasis with acute symptoms requiring emergency surgery

          -  Cholelithiasis associated with neoplastic condition of any localization or origin

          -  Usage of other antioxidants within the duration of the clinical trial

          -  Handicap and/or psychiatric condition preventing treatment accomplishment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Hern√°ndez Mojena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Dr. Salvador Allende&quot; Clinical-Surgical-Docent Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;Dr. Salvador Allende&quot; Clinical-Surgical-Docent Hospital</name>
      <address>
        <city>Havana City</city>
        <state>Havana</state>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <last_update_submitted>May 6, 2012</last_update_submitted>
  <last_update_submitted_qc>May 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dietary supplement</keyword>
  <keyword>Renalof</keyword>
  <keyword>gallstones</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallstones</mesh_term>
    <mesh_term>Cholelithiasis</mesh_term>
    <mesh_term>Cholecystolithiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

